Astrazeneca Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
AstraZeneca Pharma India Limited is navigating a complex landscape characterized by both opportunities and challenges. Management has highlighted a robust pipeline bolstered by recent regulatory approvals, particularly in oncology and biopharmaceuticals, which positions the company for potential revenue growth. However, pricing pressures and geopolitical risks remain significant concerns that could impact margins. Vista's financial outlook reflects a cautious stance, anticipating moderated revenue growth and continued margin pressure, aligning with the broader industry trends of rising input costs and pricing challenges in key markets. Despite these headwinds, the favorable currency depreciation is expected to benefit export-oriented revenues, supporting a stable growth trajectory. Over the next 12-24 months, AstraZeneca's strategic initiatives, including partnerships and AI-driven diagnostics, present opportunities for enhanced market penetration. Key watchpoints include the execution of new product launches and the impact of geopolitical factors on operational efficiency. Overall, while the company is well-positioned for long-term growth, the immediate outlook suggests a need for vigilance regarding margin pressures and market dynamics
Why We Like This Stock
- Strong pipeline supported by recent regulatory approvals enhances growth prospects
- Favorable currency depreciation is expected to boost revenues for export-oriented products
- Strategic initiatives, including partnerships and AI-driven diagnostics, may improve market penetration
Things To Watch Out For
- Pricing pressures in key markets could adversely affect profitability
- Geopolitical risks may impact operational efficiency and margins
- Rising input costs are exerting pressure on margins across the sector
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,296 | 1,716 | 2,276 | 2,453 | 2,924 |
| Profit Before Tax (Cr.) | 204 | 252 | 257 | 249 | 306 |
| PBT Margin | 15.7% | 14.7% | 11.3% | 10.2% | 10.4% |
| Net Profit (Cr.) | 370 | 331 | 192 | 185 | 226 |
| Earnings Per Share | 148.1 | 132.5 | 76.8 | 73.8 | 90.5 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes. The company serves distributors, hospitals, and government institutions. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.